Biology and genetics

Pan-PIM Kinase Inhibition Provides a Novel Therapy for Treating Hematological Cancers. Garcia PD et al. Clin Cancer Res. 2014 Jan 28. [Epub ahead of print]. Mechanisms and consequences of constitutive NF-κB activation in B-cell lymphoid malignancies. Nagel D et al. Oncogene. 2014 Jan 27. doi: 10.1038/onc.2013.565. [Epub ahead of print]. Cyclin D1 Amplification in Multiple…


Supportive care

Extracorporeal membrane oxygenation in adult patients with hematologic malignancies and severe acute respiratory failure.Wohlfarth P et al. Crit Care. 2014 Jan 20;18(1):R20. [Epub ahead of print].Clearance of Drugs for Multiple Myeloma Therapy During In Vitro High-Cutoff Hemodialysis.Krieter DH et al. Artif Organs. 2014 Jan 7. doi: 10.1111/aor.12248. [Epub ahead of print].Acupuncture for neuropathic pain due…


Complications of myeloma and its treatments

Continuous low-dose cyclophosphamide and prednisone in the treatment of relapsed/refractory multiple myeloma with severe heart failure.Zhou F et al. Leuk Lymphoma. 2014 Jan 28. [Epub ahead of print].Bortezomib just for induction or also for maintenance in myeloma patients with renal impairment?San Miguel JF. Haematologica. 2014 Jan;99(1):5-6. doi: 10.3324/haematol.2013.100982.Management of bone disease in multiple myeloma.Terpos E…


Current treatments

Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: Updated Follow-Up and Improved Survival. Palumbo A et al. J Clin Oncol. 2014 Jan 21. [Epub ahead of print]. Autologous stem cell transplantation for elderly patients with newly diagnosed multiple myeloma in the era of novel agents. Merz M et…


IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide, lenalidomide or bortezomib-containing regimens

This paper, written by an expert panel of the International Myeloma Working Group, examines the impact of novel treatments on stem cell collection in myeloma patients. It summarises the available evidence and makes recommendations to address identified issues.

NICE guidance: Improving Supportive and Palliative Care for Adults with Cancer

Following consultation on the scope of the guideline we have decided to retain Improving supportive and palliative care for adults with cancer. The title of the new guideline will be changed to End of life care for adults in the last year of life: service delivery. Where there is overlap between the two guidelines we…